The term 'endometrosis', coined in 1992 to describe chronic degenerative changes of the equine endometrium, is descriptively imprecise and readily confused with 'endometritis' and the human gynaecological condition 'endometriosis'. A …
Endometriosis is a multifaceted disease, causing debilitating pelvic pain in some patients, while being completely asymptomatic in others. The pathophysiology of endometriosis pain is not well understood and poorly correlated …
β-Glucuronidase (β-G, EC 3.2.1.31) reverses phase II glucuronidation, and microbial β-G at the gut-liver interface reactivates biliary and circulating conjugates, closing enterohepatic loops for drugs, estrogens, bile acids, and bilirubin. …
Endometriosis is a complex chronic inflammatory disease with an unclear etiology and limited treatment options, severely affecting the reproductive health and quality of life of many women. Histone deacetylases (HDACs), …
Endometriosis causes pelvic pain, dysmenorrhea (DYS), dyspareunia, and fertility issues. Linustedastat (OG-6219) is an oral, selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (HSD17β1), an enzyme involved in local estradiol biosynthesis. …
Endocrine-disrupting chemicals (EDCs) are ubiquitous environmental contaminants that interfere with hormone signalling and are increasingly linked to adverse reproductive outcomes. This viewpoint highlights emerging evidence that EDC exposure disrupts both …
Endometriosis is a chronic estrogen-dependent inflammatory disorder affecting approximately 10% of women of reproductive age. It remains a major contributor to chronic pelvic pain, infertility, and reduced quality of life. …
Endometriosis is a chronic, estrogen-dependent inflammatory condition that is marked by the growth of lesions outside the uterus, along with angiogenesis, fibrosis, immune dysregulation, and pain sensitization. There is now …
Endometriosis is a complex chronic condition, driven by estrogen, characterized by the growth of endometrial-like tissue outside the uterus. This often-debilitating disease affects millions of women globally, manifesting as severe …
Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …